<DOC>
	<DOCNO>NCT03004001</DOCNO>
	<brief_summary>The study purpose determine hypolipidemic effect Alirocumab co-administered atorvastatin level triglyceride-rich lipoprotein LDL compare monotherapy atorvastatin patient dyslipidemia secondary nephrotic syndrome .</brief_summary>
	<brief_title>Effect PCSK9-Antibody ( Alirocumab ) Dyslipidemia Secondary Nephrotic Syndrome</brief_title>
	<detailed_description>The trial randomize ( 1:1 alirocumab placebo ) , double-blinded , placebo-controlled cross-over design . The trial last 10 month include 10 week washout period study phases.Twenty adult subject dyslipidemia secondary nephrotic syndrome treat atorvastatin recruit . Alirocumab placebo co-administered biweekly . Safety , efficacy chemistry , vital sign , anthropometry monitoring adverse event also do visit .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Nephrotic Syndrome</mesh_term>
	<mesh_term>Nephrosis</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Nephrotic Syndrome ( NS ) ( FSGS , IMN NS type 2 DM ) atorvastatin LDL C &gt; = 70 mg/dl nonHDL C &gt; = 100 mg/dl Plasma trigycerides &lt; 800 mg/dl . Highly effective method contraception premenopausal woman Postmenopausal woman must amenorrheic least 12 month . homozygous FH Fibrates within 6 week screen visit Uncontrolled hypothyroidism Known history hemorrhagic stroke Known history loss function PCSK9 use systemic corticosteroid unless use replacement therapy pituitary/adrenal disease stable regimen least 6 week randomization Previous treatment least single dose alirocumab antiPCSK9 monoclonal antibody Other condition situation per protocol Laboratory finding contraindication background therapy Warnings/precautions use ( appropriate ) display respective national product label Any currently know contraindication study drug , pregnancy breastfeed infant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Severe proteinuria</keyword>
	<keyword>Dyslipidemia</keyword>
</DOC>